Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Da Silva

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Seminars in Respiratory and Critical Care Medicine|December 19, 2022
CFTR Modulators: Current Status and Evolving KnowledgeLucile Regard, Clémence Martin, Jennifer Da Silva, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2021
Reply to Kuek <i>et al.</i>: Optimism with Caution: Elexacaftor-Tezacaftor-Ivacaftor in Patients with Advanced Pulmonary DiseasePierre-Régis Burgel, Jennifer Da Silva, Jean-Louis Paillasseur, et al.
Cells|June 10, 2022
CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in FranceLucile Regard, Clémence Martin, Espérie Burnet, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 19, 2026
Persistence of residual insulin secretion in long-standing Cystic Fibrosis Related DiabetesIrene Aguilera García, Francois Mifsud, Jennifer Da Silva, et al.
Biomedicines|February 25, 2022
The War Is on: The Immune System against Glioblastoma-How Can NK Cells Drive This Battle?Lucas Henrique Rodrigues da Silva, Luana Correia Croda Catharino, Viviane Jennifer da Silva, et al.
Journal of Personalized Medicine|April 30, 2021
Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice ModelVincenzo Di Leo, Patrick J Gleeson, Fabio Sallustio, et al.
Eclinicalmedicine|September 11, 2025
Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two <i>CFTR</i> Class I variants: real-world data from the French compassionate programmePierre-Régis Burgel, Emmanuelle Girodon, Neeraj Sharma, et al.
Plos One|October 7, 2025
Blockade of mTOR ameliorates IgA nephropathy by correcting CD89 and CD71 dysfunctions in humanized miceAlexandra Cambier, Jennifer Da Silva, Julie Bex, et al.
The European Respiratory Journal|December 1, 2022
Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosisThéo Dhote, Clémence Martin, Lucile Regard, et al.
Plos One|March 17, 2026
Correction: Blockade of mTOR ameliorates IgA nephropathy by correcting CD89 and CD71 dysfunctions in humanized miceAlexandra Cambier, Jennifer Da Silva, Julie Bex, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Seminars in Respiratory and Critical Care Medicine|December 19, 2022
CFTR Modulators: Current Status and Evolving KnowledgeLucile Regard, Clémence Martin, Jennifer Da Silva, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2021
Reply to Kuek <i>et al.</i>: Optimism with Caution: Elexacaftor-Tezacaftor-Ivacaftor in Patients with Advanced Pulmonary DiseasePierre-Régis Burgel, Jennifer Da Silva, Jean-Louis Paillasseur, et al.
Cells|June 10, 2022
CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in FranceLucile Regard, Clémence Martin, Espérie Burnet, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 19, 2026
Persistence of residual insulin secretion in long-standing Cystic Fibrosis Related DiabetesIrene Aguilera García, Francois Mifsud, Jennifer Da Silva, et al.
Biomedicines|February 25, 2022
The War Is on: The Immune System against Glioblastoma-How Can NK Cells Drive This Battle?Lucas Henrique Rodrigues da Silva, Luana Correia Croda Catharino, Viviane Jennifer da Silva, et al.
Journal of Personalized Medicine|April 30, 2021
Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice ModelVincenzo Di Leo, Patrick J Gleeson, Fabio Sallustio, et al.
Eclinicalmedicine|September 11, 2025
Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two <i>CFTR</i> Class I variants: real-world data from the French compassionate programmePierre-Régis Burgel, Emmanuelle Girodon, Neeraj Sharma, et al.
Plos One|October 7, 2025
Blockade of mTOR ameliorates IgA nephropathy by correcting CD89 and CD71 dysfunctions in humanized miceAlexandra Cambier, Jennifer Da Silva, Julie Bex, et al.
The European Respiratory Journal|December 1, 2022
Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosisThéo Dhote, Clémence Martin, Lucile Regard, et al.
Plos One|March 17, 2026
Correction: Blockade of mTOR ameliorates IgA nephropathy by correcting CD89 and CD71 dysfunctions in humanized miceAlexandra Cambier, Jennifer Da Silva, Julie Bex, et al.
Pageof 5